238 citations
,
November 2016 in “Journal of The American Academy of Dermatology” In this study, tofacitinib was reported to improve scalp hair regrowth in patients with severe alopecia areata, alopecia totalis, and alopecia universalis, showing a higher response in alopecia areata.
54 citations
,
September 2019 in “Journal of the European Academy of Dermatology and Venereology” This study found that tofacitinib shows reasonable effectiveness for treating alopecia areata with mild adverse effects, although more large-scale randomized trials are needed to fully assess its safety and efficacy.
39 citations
,
January 2019 in “Journal of the American Academy of Dermatology” In this study, three children with severe alopecia treated with systemic tofacitinib showed significant hair regrowth, suggesting it may be a potential option for those unresponsive to conventional therapy.
17 citations
,
January 2019 in “Dermatologic Therapy” The article in Dermatologic Therapy discusses clinical experiences with using tofacitinib to treat alopecia areata in 63 patients, but no specific results are reported in the abstract.
11 citations
,
November 2019 in “Journal of the American Academy of Dermatology” This study suggests that oral tofacitinib may be an effective treatment for beard regrowth in men with alopecia areata of the beard, with a strong correlation observed between beard and scalp hair regrowth.
2 citations
,
April 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” This systematic review evaluated the safety of JAK-inhibitors for alopecia areata, finding that most adverse events were mild and systemic formulations were well-tolerated; however, increased rates of certain infections and laboratory abnormalities were noted, with isolated severe cases but no fatal outcomes.
May 2024 in “Journal of cosmetic dermatology” In this retrospective study, oral tofacitinib treatment for at least 6 months improved scalp hair loss in 69.1% of alopecia areata patients, with patchy AA cases responding better compared to other subtypes, and no significant adverse effects were reported.
November 2023 in “Journal of Investigative Dermatology” JAK inhibitors are effective and generally safe for treating alopecia areata, but monitoring for side effects is important.
January 2024 in “Dermatologic therapy” In this study, pediatric patients with alopecia areata treated with systemic tofacitinib showed significant improvement at 12 months, but the small sample size and retrospective design limit conclusions about its effectiveness.
20 citations
,
February 2023 in “American Journal of Clinical Dermatology” In this study, 40.9% of patients taking 4 mg baricitinib and 21.2% taking 2 mg achieved significant hair regrowth over 52 weeks, indicating potential long-term benefits for adults with severe alopecia areata without introducing new safety concerns.
June 2023 in “British Journal of Dermatology” This study observed that baricitinib treatment led to significant improvements in hair regrowth and quality of life scores in adults with severe alopecia areata over 24 weeks, with an acceptable safety profile as most adverse effects were transient.
3 citations
,
May 2023 in “Clinical drug investigation” This study reviewed the safety of JAK inhibitors for alopecia areata, finding that common side effects included headache and acne, with varying risks for respiratory infections and no increased risk of serious adverse events.
December 2025 in “International Journal of Innovative Technologies in Social Science” This study found that ritlecitinib, approved for alopecia areata in patients aged 12 and older, has an acceptable safety profile with mild to moderate side effects and no increase in serious adverse events compared to placebo.
25 citations
,
November 2022 in “British journal of dermatology/British journal of dermatology, Supplement” In this analysis, safety data from two clinical trials showed that baricitinib for severe alopecia areata had predictable side effects like infections and elevated CPK, with some serious adverse events noted at low incidence rates; no deaths were reported.
9 citations
,
October 2019 in “Dermatologic Therapy” This study observed that oral tofacitinib was reasonably well-tolerated but had limited efficacy in treating alopecia areata, with a clinical response seen in 41.4% of patients over six months.
6 citations
,
May 2023 in “Drugs” This study reports that baricitinib was more effective than placebo in promoting hair growth in adults with severe alopecia areata after 36 weeks of treatment in clinical trials.
June 2026 in “International Journal of Research in Medical Sciences” This study compared the adverse effects of baricitinib and methotrexate in treating severe alopecia areata and found baricitinib to have a better safety profile, though it was associated with increased cholesterol, triglyceride, and LDL levels.
June 2023 in “Value in Health” Alopecia areata treatments often cause headaches and infections, highlighting the need for safer options.
3 citations
,
March 2020 in “International Journal of Dermatology” This correspondence about the treatment of chronic alopecia areata with tildrakizumab reports no clinical results; the authors present an open-label pilot study setup.
October 2023 in “The Open Dermatology Journal” Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.
16 citations
,
February 1986 in “Clinica Chimica Acta” Zinc deficiency is linked to respiratory infections in children.
May 2022 in “Голова и шея.” In this study, managing laryngectomy patients during the COVID-19 pandemic requires special precautions due to their unique respiratory challenges, emphasizing the need for protective equipment and postponement of non-essential procedures to reduce infection risks for patients and health care providers.
January 2023 in “Brazilian Journals Editora eBooks” Surgery to fix a broken upper arm bone can sometimes lead to nerve damage.
2 citations
,
August 2022 in “Clinical Case Reports” This case report describes a 17-year-old girl with telogen effluvium and severe hair loss following a suspected COVID-19 infection and a history of similar episodes since childhood.
11 citations
,
October 2021 in “Orphanet journal of rare diseases” This study found that patients with RASopathies have lower serum IgA and CD8 levels compared to controls, indicating a potential risk for developing autoimmune disorders.
March 2021 in “Research Square (Research Square)” This study found that patients with RASopathies demonstrated lower levels of serum IgA and CD8 T cells compared to controls, potentially indicating an increased risk of developing autoimmune disorders.
August 2018 in “Journal of The American Academy of Dermatology” A 54-year-old man with painful skin blisters and fever was diagnosed with Sweet syndrome and successfully treated with corticosteroids.
1 citations
,
July 2026 in “Dermatology and Therapy” In this study, JAK inhibitors for treating alopecia areata and atopic dermatitis were generally well tolerated in a real-world setting, with most adverse events being mild or moderate and rare serious cases resembling the general population incidence.
March 2026 in “Journal of Pakistan Association of Dermatologists” In this quasi-experimental study, 24-week tofacitinib treatment significantly improved hair regrowth in South Asian patients with alopecia areata, but a high relapse rate post-withdrawal signals the need for continuous treatment strategies.
November 2025 in “SKIN The Journal of Cutaneous Medicine” This phase 3 trial found that over 50% of adolescents with severe alopecia areata achieved successful hair regrowth after 52 weeks on baricitinib 4-mg, with no new safety concerns reported compared to existing safety profiles.